Akari Therapeutics Plc — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 12/100
What the filing says
Akari Therapeutics filed Form 8-K reporting Item 5.07 (submission of matters to a vote of security holders) for period ending 2026-06-30. The filing contains only boilerplate SEC cover page information and XBRL data format files. No specific voting matters, proposals, vote counts, outcomes, or material corporate actions are detailed in the publicly available filing text provided.
Why this rating
Routine Form 8-K with no substantive disclosure of voting outcomes or business impacts. No dollar amounts, shareholder counts, or material decisions revealed.
Extracted items
- 5.07 shareholder vote
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.